Expectations, validity, and reality in pharmacogenetics
- 30 September 2010
- journal article
- review article
- Published byĀ Elsevier BVĀ inĀ Journal of Clinical Epidemiology
- Vol.Ā 63Ā (9), 960-969
- https://doi.org/10.1016/j.jclinepi.2009.09.006
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsThe Pharmacogenomics Journal, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- Genome-wide association studies: potential next steps on a genetic journeyHuman Molecular Genetics, 2008
- Ī±-Adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES)American Heart Journal, 2008
- A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?JNCI Journal of the National Cancer Institute, 2008
- Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling AnalysisJNCI Journal of the National Cancer Institute, 2008
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenetics and Genomics, 2006
- A road map for efficient and reliable human genome epidemiologyNature Genetics, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005